Abstract
Two authors (QJY and ZN) independently assessed each study for eligibility. Discrepancies were resolved by consultation with a third author (SYC). Studies were included in the review if they fulfilled all the following criteria: (1) the work was an original research article published in English or Chinese; (2) human samples were analyzed; (3) the study examined TAAbs for diagnosing lung cancer and contained a control group; and (4) sufficient data were reported to calculate true positive (TP), false positive (FP), false negative (FN), and true negative (TN) rates for TAAbs. Case reports or case series involving fewer than 10 patients, conference proceedings, reviews, letters to the editor, and case reports were excluded because of the limited data reported.
Quality assessment and data extraction
The quality of the included studies was scored independently by two authors (QJY and ZN) according to the criteria of the Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) [22] . Four key domains were assessed (patient selection, index test, reference standard, flow and timing), and each domain contained seven "yes/no/unclear" questions. The following data were retrieved from each study: authors, country, tumor type, specimen type, gold standard, assay methods, and 2-by-2 tables showing rates of TP, TN, FP and FN. Detailed information about controls was also extracted. Controls in the included studies were either healthy or they had benign pulmonary diseases.
Data synthesis and analysis
Data were completed in Excel, then transferred to STATA 14.0 (Stata, College Station, TX, USA) and Review Manager 5.2 (The Cochrane Collaboration, Copenhagen, Denmark) for statistical analysis. For each study, pooled sensitivity and specificity and their 95% confidence intervals (CIs) were calculated using the bivariate random-effects model [23] . To provide potentially more clinically relevant outcomes, we also calculated for each TAAb a likelihood ratio, diagnostic odds ratio (DOR), and area under the curve (AUC).
Two authors (QJY and ZN) assessed studies for possible overlap in the populations analyzed. Data were pooled from overlapping populations as long as the different studies reported on different TAAbs or TAAb combinations. Otherwise, if studies with overlapping populations reported on the same TAAbs or TAAb combination, only the data from the largest study were used.
Heterogeneity induced by the nonthreshold effect was assessed using the Cochran Q method and the test of inconsistency (I 2 ). If P < 0.05 or I 2 > 50%, heterogeneity exists [24] . Furthermore, subgroup and regression analyses were performed to explore potential sources of heterogeneity. Deeks' test was used to detect publication bias. All P values were calculated using a 2-tailed test, and P < 0.05 was regarded as statistically significant.
Results

Basic information about the included studies
A total of 468 articles were initially identified, of which 327 were excluded as duplicates, reviews, news reports, meeting records or other publication types that did not focus on lung cancer (Fig. 1) . In the end, 53 articles were included, which examined the diagnostic efficacy of TAAbs against p53, c-myc, Survivin, NY-ESO-1, Cyclin B1, CAGE, GBU 4-5, p16, HuD and SOX2 [17, . Other TAAbs were excluded from the review because relevant data were available from fewer than 3 articles . Five of the included studies examined only small-cell lung cancer (SCLC) [45, 50, 52, 58, 67] , and eight included only non-small cell lung cancer (NSCLC) [28, 47, 54, 55, 57, 59, 64, 109] . A total of 50 articles were based on serum specimens, while the remaining 3 were based on plasma samples. In 41 articles, diagnosis of lung cancer was based on histopathology or cytology; 12 articles did not report the standards used to diagnose lung cancer. A total of 50 articles measured TAAb levels using enzyme-linked immunosorbent assays (ELISAs), and the remaining 3 articles using immunoblotting (Supplementary Table 1 Study quality QUADAS-2 assessment of included studies showed that most studies had low risk of bias ( Fig. 2 and Fig.  3 ) and that the studies were suitable for quantitative synthesis.
Diagnostic performance of single TAAbs
Data were metaanalyzed using a bivariate model ( Table 1 
Diagnostic performance of p53 TAAb for early stage I/II lung cancer
We also focused on the diagnostic value of TAAb for early stage lung cancer. Six studies on p53 TAAb [29, 30, 37, 39, 40, 51] were included for the meta-analysis, which reported the positive rate for this TAAb in different stages of lung cancer. The pooled sensitivity and specificity of p53 TAAb for early stage I/II lung cancer was 0.13 (95%CI 0.04-0.33) and 0.98 (95%CI 0.95-0.99), respectively. The AUC was 0.93 (95%CI 0.90-0.95), indicating a relatively high level of overall diagnostic accuracy of p53 TAAb for early stage lung cancer. Other TAAbs were not analyzed because fewer than three studies reported the positive rates of these TAAbs in different stages of lung cancer.
Subgroup analyses
Mutations in the p53 gene are present in up to 50% of NSCLC cases and 80% of SCLC cases [110] . Therefore we performed subgroup analysis to identify whether the presence of p53 TAAb could differentiate NSCLC (15 studies, 2, 478 patients) and SCLC (9 studies, 1, 630 patients). We also examined whether the same was true for NY-ESO-1 TAAb. The [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] ; and AUC, 0.54 (95%CI 0.5-0.58). These results suggest that, at least in the case of the p53 TAAb, using healthy individuals as controls provides higher diagnostic efficiency than using patients with chronic pulmonary disease.
Meta-regression analyses
Significant heterogeneity existed among studies of the p53 TAAb: I 2 values were 91.63% for sensitivity, 69.11% for specificity (Fig. 5) , 13.88% for PLR, 85.48% for NLR and 100% for DOR (all P < 0.05). Therefore we conducted meta-regression analysis for data on this TAAb in which the odds ratio (OR) was used for binary classification of data, and log OR was used as the response variable. The covariates were the patient's geographic region, type of sample and assay method. The residual I 2 (I 2 -res) value was 29.74%, suggesting that 29.74% of the residual variation could be explained by the heterogeneity, while the remaining 70.26% was explained among the studies. The adjusted R-squared was 41.92% in the covariate model, which may explain the variation among the studies. This variation may relate to the patient's geographic region (P = 0.034; Table 2 ), but it was not related to type of sample or assay method. Thus we conducted subgroup analysis of p53 TAAb performance based on the patient's geographic region (Table 3) . Conclusive cut-off values could not be identified in this regression because of inaccurate data and the lack of a uniform standard. Meta-regression analysis was not performed for other TAAbs because of the limited number of studies. 
Sensitivity analysis
Sensitivity analysis for p53 TAAb was performed to make sure that our findings were not overly influenced by any single study (Fig.  6) . Comparison of pooled diagnostic parameters using all studies or all studies except for three outliers [33, 36, 37] showed that excluding the three studies reduced sensitivity from 0.19 to 0.17, DOR from 10 to 9 and PLR from 8.6 to 7.9, whereas it increased NLR from 0.83 to 0.85 and AUC from 0.82 to 0.91. Specificity in both cases was 0.98. Excluding the three studies reduced the I 2 for heterogeneity in sensitivity from 91.63% to 89.47% and in specificity from 69.11% to 31.03%. These results suggest that our meta-analysis with the full set of studies is reliable.
Publication bias evaluation
Except for studies of p53 TAAb and Survivin TAAb for diagnosing NSCLC and lung cancer, respectively, Deeks' funnel plots showed no evidence of publication bias for the TAAbs (all P > 0.05; Table 1 ). 
Discussion
The mortality of lung cancer is due primarily to late detection; early diagnosis is crucial for asymptomatic patients. TAAbs can be detected in many cancer patients prior to symptom onset [17, 48] , raising the possibility that they may facilitate early diagnosis. Indeed, healthy people usually lack these TAAbs, even those at higher risk of lung cancer. These promising characteristics have led many researchers to explore the diagnostic potential of assaying TAAbs in peripheral blood as serological markers of lung cancer.
One recent review [109] indicated different single or combinations of multiple TAAbs have different diagnostic abilities for detecting patients at all stages of lung cancer, while the review did not report sensitivity, specificity and AUC for each TAAb. In our systematic review, each TAAb was analyzed using bivariate mixedeffect models, and larger numbers of references were included. Our systematic review of the available evidence suggests that TAAbs against p53, NY-ESO-1, Survivin, c-myc, HuD, SOX2, Cyclin B1, CAGE, GBU 4-5 and p16 show high specificity for diagnosing lung cancer but insufficient sensitivity. For example, PLRs were >10 (indicating >10-fold difference between pre-and post-test) only for TAAbs against Survivin, HuD, or SOX2 (Table 1) . This means that a positive result for any of these TAAbs indicates a relatively high probability of lung cancer, which is consistent with the high specificities reported for these TAAbs. However, the NLRs for these TAAbs were not low, indicating an inability to exclude the possibility of lung cancer. SCLC progresses rapidly and disseminates widely, giving rise to low 5-year survival [115] . Most cases of SCLC (60-70%) are diagnosed at the extensive stage, reducing the possibilities for good prognosis [116] [117] [118] . This highlights the urgent need to develop serum biomarkers that might allow diagnosis of SCLC. Our meta-analysis suggests that p53 and NY-ESO-1 TAAbs show better diagnostic performance for SCLC than for NSCLC. A previous study suggested that the Hu TAAb may be useful in early diagnosis of SCLC [119] . Therefore future studies should investigate whether combining TAAbs against Hu, p53 and NY-ESO-1 can facilitate SCLC diagnosis.
The EarlyCDT®-Lung Test is a novel TAAb diagnostic test for the early detection of lung cancer allowing stratification of individuals according to their risk of developing lung cancer, which could permit a targeted approach to LDCT scanning for early lung cancer detection. The EarlyCDT®-Lung Test measures seven TAAbs against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2, which identify 47% of lung cancers with a high specificity of 90% [2, 53, 111, 114] . Moreover, the TAAbs detected in the test have not been shown to vary with age, gender or ethnicity [120] , making the test more suitable for clinical screening. However, combinations of TAAbs may be associated with higher sensitivity but lower specificity than single TAAbs.
Survivin is an apoptosis-suppressing protein, promoting cell proliferation and inhibiting apoptosis [121, 122] . Once Survivin is overexpressed in lung cancer, it may lead to antibody responses to this protein. Antibodies to Survivin are one of the tumor-associated autoantibodies described most frequently in lung cancer [123, 124] . Our analysis shows that AUC and specificity of Survivin are relatively high. Future research should examine wehther Survivin should be included in the EarlyCDT®-Lung Test.
The present meta-analysis has some limitations. First, our exclusion of conference abstracts, letters to journal editors and unpublished data may have given rise to publication bias, such that our results overestimate actual diagnostic performance. Second, description of methodology was incomplete in some studies, leading to a QUADAS-2 assessment of "unclear". Third, a single TAAb was detected in a relatively small population of patients with lung cancer, which means that relying on TAAb individually may lead to a high FN rate. Fourth, most studies used ELISA to analyze serum TAAbs, while diagnostic cut-off values have not been established for lung cancer. Therefore, more researches are needed to confirm the optimized TAAb cut-off values. Fifth, all but one study [41] was retrospective, increasing the risk of bias in patient selection. Sixth, substantial heterogeneity was detected. In the case of studies of p53 TAAb, the heterogeneity reflected cancer type, source of control, and patient's geographic region as well as unidentified factors. Seventh, some studies did not report smoking status, especially in healthy controls, which leads to selection bias. For instance, the prevalence of p53-TAAbs was higher in smokers than in non-smokers [125, 126] . Moreover, smoking status was found to be the major contributor to levels of anti-Survivin TAAbs [127] . Future studies on TAAbs should consider smoking status. Our results highlight the need for more rigorous studies of TAAb combinations in the diagnosis of lung cancer.
Conclusion
TAAbs show low sensitivity and high specificity as serum diagnostic markers of lung cancer. Our results indicate that combinations or panels of autoantibodies may improve sensitivity but at the cost of specificity. Future research should focus on novel TAAb panels that may offer better diagnostic performance.
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